Activist Starboard sells Pfizer stake after pushing for changes

Activist investor Starboard Value has liquidated its position in Pfizer (PFE.N) during the third quarter, abandoning its year-long campaign to boost the drugmaker's share price, which saw a decline in market value during Starboard's involvement. Concurrently, the hedge fund also exited its investment in Fortrea Holdings (FTRE.O) in Q3, an investment that preceded a nearly 50% drop in Fortrea's share price, highlighting recent challenges in Starboard's activist plays.

Analysis

Activist investor Starboard Value has liquidated its positions in both Pfizer (PFE.N) and Fortrea Holdings (FTRE.O) during the third quarter, as per a recent regulatory filing. This move signals the cessation of Starboard's year-long activist campaign at Pfizer, which aimed to boost the drugmaker's share price. The general sentiment surrounding this news is moderately negative, with specific negative sentiment for both PFE and FTRE.

During Starboard's involvement, Pfizer's market value declined from approximately $162 billion to $142 billion, indicating significant underperformance despite activist pressure. Similarly, Starboard's investment in Fortrea, announced in October 2023, preceded a nearly 50% drop in its share price. These outcomes suggest a challenging period for Starboard's recent activist plays in these specific companies.

Starboard had previously acquired a roughly $1 billion stake in Pfizer when shares were trading at half their pandemic-era high, with founder Jeffrey Smith advocating for management accountability. The exit from both positions, particularly after significant share price declines, implies a lack of success in driving desired changes or value appreciation. This development could impact investor sentiment regarding the efficacy of activist campaigns in the current market environment, especially within the healthcare sector.

Key Decisions for Investors

• Investors should re-evaluate Pfizer's standalone growth prospects and management effectiveness, given Starboard's exit after a period of market value decline.
• Consider the implications for other activist-targeted companies, as Starboard's unsuccessful campaigns in Pfizer and Fortrea suggest potential challenges in driving value through activism in the current environment.
• Monitor broader market and sector-specific sentiment, as the negative outcomes for both PFE and FTRE could signal underlying issues beyond individual company performance.